Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Virginia Kwitkowski

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical Trials (London, England)|August 3, 2017
Commentary on Heath et alVirginia Kwitkowski, Selena Daniels, Gregory Reaman, et al.
Blood Reviews|April 4, 2020
Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentationBindu Kanapuru, Harpreet Singh, Virginia Kwitkowski, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 27, 2020
FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host diseaseBellinda L King-Kallimanis, Tanya Wroblewski, Virginia Kwitkowski, et al.
Cancer|March 3, 2007
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancerEdwin M Posadas, Meghan S Liel, Virginia Kwitkowski, et al.
The Oncologist|August 19, 2018
FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the <i>BRAF</i>V600 MutationPatricia A Oneal, Virginia Kwitkowski, Lola Luo, et al.
Cancer|June 15, 2007
A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profilingEdwin M Posadas, Virginia Kwitkowski, Herbert L Kotz, et al.
Cancer|December 31, 2013
Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspectiveEthan Basch, Ann Marie Trentacosti, Laurie B Burke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2012
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphomaR Angelo de Claro, Karen McGinn, Virginia Kwitkowski, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical Trials (London, England)|August 3, 2017
Commentary on Heath et alVirginia Kwitkowski, Selena Daniels, Gregory Reaman, et al.
Blood Reviews|April 4, 2020
Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentationBindu Kanapuru, Harpreet Singh, Virginia Kwitkowski, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 27, 2020
FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host diseaseBellinda L King-Kallimanis, Tanya Wroblewski, Virginia Kwitkowski, et al.
Cancer|March 3, 2007
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancerEdwin M Posadas, Meghan S Liel, Virginia Kwitkowski, et al.
The Oncologist|August 19, 2018
FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the <i>BRAF</i>V600 MutationPatricia A Oneal, Virginia Kwitkowski, Lola Luo, et al.
Cancer|June 15, 2007
A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profilingEdwin M Posadas, Virginia Kwitkowski, Herbert L Kotz, et al.
Cancer|December 31, 2013
Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspectiveEthan Basch, Ann Marie Trentacosti, Laurie B Burke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2012
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphomaR Angelo de Claro, Karen McGinn, Virginia Kwitkowski, et al.
Pageof 1